$1,590,000 of GILEAD SCIENCES INC lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to pharmaceuticals and intellectual property protection including technology transfer, patent rights and funding. Funding for policies relating to domestic and international HIV, Hepatitis C, oncology, and public health activities via appropriations. Advocacy regarding drug pricing proposals, including provisions modifying the Inflation Reduction Act and government purchasing proposals. Legislative and regulatory proposals to change international and domestic corporate tax law and policy. Advocate on domestic and global drug pricing proposals, international trade and protection of intellectual property; global supply chain issues, including the Medical Supply Chain Resiliency Act and tariffs; compulsory licensing and other IP issues in multiple countries. Advocate on drug pricing proposals. Proposals to expand access to HIV treatment and prevention therapies including: Ryan White Care Act reauthorization; PEPFAR; HIV/AIDS access to care, research, testing and treatment. Hepatitis C screening and linkage to care programs; coverage and reimbursement policy for Hepatitis C, HIV and oncology portfolio. Issues related to triple negative breast cancer (TNBC) and early detection and screenings for breast cancer. Advocate in favor of 340B program reforms and changes. Issues related to developing treatments and therapies, including: manufacturing, clinical trials, reimbursement and coverage. Advocate for provisions modifying the Inflation Reduction Act and other drug pricing proposals. HCV testing, screening and linkage to care programs. Medicaid and Medicare coverage, access and reimbursement issues for Hepatitis C, HIV, oncology products, and COVID-19 therapies and prevention including Medicare Part B proposals, and Medicare Part D reform and benefit redesign. CMS rules, including those related to payments in Medicare, Medicaid drug rebates, and proposed CMMI demonstrations."
You can find more data on corporate lobbying on Quiver Quantitative.
GILD Congressional Stock Trading
Members of Congress have traded $GILD stock 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $GILD stock by members of Congress over the last 6 months:
- REPRESENTATIVE JARED MOSKOWITZ has traded it 2 times. They made 2 purchases worth up to $30,000 on 05/06 and 0 sales.
- REPRESENTATIVE JOSH GOTTHEIMER purchased up to $15,000 on 01/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
GILD Insider Trading Activity
GILD insiders have traded $GILD stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.
Here’s a breakdown of recent trading of $GILD stock by insiders over the last 6 months:
- DANIEL PATRICK O'DAY (Chairman & CEO) has made 0 purchases and 15 sales selling 301,280 shares for an estimated $42,330,186.
- JOHANNA MERCIER (Chief Comm & Corp Aff Officer) has made 0 purchases and 13 sales selling 68,000 shares for an estimated $9,617,516.
- ANDREW D DICKINSON (Chief Financial Officer) has made 0 purchases and 6 sales selling 18,000 shares for an estimated $2,481,646.
- JEFFREY BLUESTONE sold 5,000 shares for an estimated $617,500
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
GILD Hedge Fund Activity
We have seen 954 institutional investors add shares of GILD stock to their portfolio, and 955 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 6,326,800 shares (+9.6%) to their portfolio in Q1 2026, for an estimated $871,516,700
- BLACKROCK, INC. removed 4,184,605 shares (-3.4%) from their portfolio in Q1 2026, for an estimated $576,429,338
- BARCLAYS PLC removed 3,833,287 shares (-42.1%) from their portfolio in Q1 2026, for an estimated $528,035,284
- BANK OF AMERICA CORP /DE/ removed 3,142,684 shares (-13.6%) from their portfolio in Q1 2026, for an estimated $432,904,721
- QUBE RESEARCH & TECHNOLOGIES LTD removed 2,425,986 shares (-95.2%) from their portfolio in Q1 2026, for an estimated $334,179,571
- WELLINGTON MANAGEMENT GROUP LLP removed 2,369,313 shares (-14.9%) from their portfolio in Q1 2026, for an estimated $326,372,865
- GOLDMAN SACHS GROUP INC added 2,316,632 shares (+26.5%) to their portfolio in Q1 2026, for an estimated $319,116,058
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
GILD Analyst Ratings
Wall Street analysts have issued reports on $GILD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Needham issued a "Buy" rating on 02/11/2026
To track analyst ratings and price targets for GILD, check out Quiver Quantitative's $GILD forecast page.
GILD Price Targets
Multiple analysts have issued price targets for $GILD recently. We have seen 13 analysts offer price targets for $GILD in the last 6 months, with a median target of $165.0.
Here are some recent targets:
- Matthew Harrison from Morgan Stanley set a target price of $166.0 on 07/08/2026
- Gregory Renza from Truist Securities set a target price of $156.0 on 07/07/2026
- Brian Abrahams from RBC Capital set a target price of $120.0 on 07/07/2026
- Morten Herholdt from HSBC set a target price of $155.0 on 07/06/2026
- Carter Gould from Cantor Fitzgerald set a target price of $155.0 on 07/06/2026
- Michael Okunewitch from Maxim Group set a target price of $165.0 on 05/20/2026
- Geoff Meacham from Citigroup set a target price of $165.0 on 04/13/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
